Journal
LEUKEMIA RESEARCH
Volume 34, Issue 5, Pages 610-614Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2009.08.010
Keywords
Elderly acute myeloid leukemia; Low-dose chemotherapy; Cytarabine; Aclarubicin; Granulocyte colony-stimulating factor; CAG
Categories
Funding
- Japanese Ministry of Education, Culture, Sport, Science and Technology
- Japanese Ministry of Health, Labor and Welfare
Ask authors/readers for more resources
We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 years were all registered. Thirty-three of 68 patients (49%) achieved remission. Median disease-free survival was 10 months and overall survival was nine months. Performance status after chemotherapy in patients who achieved remission was generally favorable. The present study demonstrates that CAG therapy is efficacious and well tolerated in the majority of elderly patients. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available